> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Akari Gains ‘Fast Track’ for Coversin
- URL: https://www.fdaweb.com/akari-gains-fast-track-for-coversin/
- Published: 2017-03-31T12:00:00.000Z
- Updated: 2026-09-14T22:15:08.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138348

FDA has granted Akari Therapeutics a fast track designation for Coversin for treating paroxysmal nocturnal hemoglobinuria (PNH) in patients who have polymorphisms conferring eculizumab resistance. Coversin is described by the company as a “second-generation complement inhibitor that acts on complement component-C5, preventing the release of C5a and the formation of C5b-9 (also known as the membrane attack complex or MAC), and independently also inhibits LTB4 activity.”

  
Akari is evaluating Coversin in two Phase 2 clinical trials. The first is evaluating the drug in patients with PNH who have never received a complement blocking therapy. The second is evaluating patients with PNH and C5 polymorphisms resistant to eculizumab.